Clinical Trial

Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 6, 2023 (before its estimated August 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
It is a RCT aimed to evaluate the Progression Free Survival of Camrelizumab combined with apatinib and temozolomide as First Line Therapy in Advanced Acral Melanoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-03-16.
Status change: Not Yet Recruiting → Recruiting 2023-09-04
Trial Details
NCT Number NCT05789043
Lead Sponsor Peking University Cancer Hospital & Institute
Conditions Acral Melanoma
Enrollment 140 participants
Start Date 2023-03-21
Primary Completion 2026-08-15 (estimated)
Study Completion 2027-02-15 (estimated)
Updated on ClinicalTrials.gov 2023-09-06